Progyny, Inc.

Progyny, Inc. has achieved a new 52-week high, reflecting its strong market performance. The company has delivered a 31.05% return over the past year, significantly outperforming the S&P 500. With solid financial metrics, including a net-debt-free status and impressive growth in net sales and operating profit, Progyny demonstrates robust financial health.

Progyny, Inc. has achieved a new 52-week high, reflecting its strong performance with a 31.72% return over the past year. The company, with a market cap of USD 1,414 million, shows solid financial health, robust growth in sales and profits, and is net-debt free, enhancing its stability.

Progyny, Inc. has achieved a new 52-week high, reflecting its strong market performance and solid financial metrics. The company has seen significant growth in net sales and operating profit, while maintaining a net-debt-free status and high institutional ownership, indicating robust confidence in its fundamentals.

Progyny, Inc. has recently experienced a valuation grade adjustment, reflecting a more favorable assessment of its financial metrics. Key indicators include a P/E ratio of 32 and a strong return on capital employed of 36.03%. The company also reported significant operating cash flow and a decrease in raw material costs.

Progyny, Inc. experienced notable stock volatility on February 27, 2026, with a significant intraday decline. Over the past week and month, the stock has faced substantial drops, reflecting ongoing challenges. Despite this, the company shows strong long-term fundamentals, though a recent decrease in promoter stake raises concerns about future confidence.

Progyny, Inc. has reached a new 52-week low, reflecting a significant decline over the past year. Despite strong long-term fundamentals, including solid growth rates and return on equity, the company faces challenges due to decreased promoter confidence and underperformance compared to broader market indices.

Progyny, Inc. has recently seen a stock price increase, reflecting its current market dynamics. The company has experienced significant volatility over the past year, with a notable trading range. Technical indicators present mixed signals, and while Progyny outperformed the S&P 500 in the past week, its longer-term performance has been less favorable.

Progyny, Inc. has recently adjusted its evaluation, reflecting changes in its market position and technical indicators. The company maintains strong long-term fundamentals, with a notable Return on Equity of 16.65% and impressive growth in net sales and operating profit. Its low debt-to-equity ratio highlights effective financial management.

Progyny, Inc. has shown remarkable stock performance, significantly outperforming the S&P 500 over various timeframes. The company reports strong financial fundamentals, including a high Return on Equity and impressive growth rates in net sales and operating profit, alongside a low debt-to-equity ratio and full institutional ownership.

Progyny, Inc. has recently adjusted its valuation, with its stock price rising to $22.37. Over the past year, the company has achieved a 35.33% return, outperforming the S&P 500. Key metrics include a P/E ratio of 35 and a return on capital employed of 34.17%, indicating strong financial performance.

Progyny, Inc. has recently adjusted its valuation metrics, reporting a P/E ratio of 35 and a price-to-book value of 3.98. The company exhibits strong returns, with a ROCE of 34.17% and an ROE of 11.24%. Despite recent stock price declines, it has achieved a year-to-date return of 12.12%.

Progyny, Inc. has recently seen a revision in its evaluation, with its stock price at $20.19. The company has experienced significant volatility over the past year, with mixed technical indicators reflecting varying trends. Despite recent underperformance compared to the S&P 500, Progyny has shown resilience with positive year-to-date and one-year returns.